[Efficacy of recombinant activated factor VII for treatment of life-threatening bleeding in cardiac surgery].
Hamdani
M
M
Bouzguenda
H
H
Jebali
M A
MA
Ferjani
M
M
Ziadi
M
M
Chenik
S
S
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001021:Aortic Valve / Q000601:surgery; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D016913:Blood Component Transfusion; D016063:Blood Loss, Surgical; D000077144:Clopidogrel; D004697:Endocarditis, Bacterial / Q000601:surgery; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D019918:Heart Valve Prosthesis Implantation; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011229:Preanesthetic Medication; D011994:Recombinant Proteins / Q000627:therapeutic use; D012769:Shock / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000601:surgery; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000627:therapeutic use
D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D017984:Enoxaparin; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D014148:Tranexamic Acid; D005167:Factor VII; D006493:Heparin; D000077144:Clopidogrel; C103587:recombinant FVIIa; D015942:Factor VIIa; D013988:Ticlopidine; D001241:Aspirin; D009638:Norepinephrine